December 5, 2023
Dr. Frances Chung, a clinician investigator at UHN's Krembil Brain Institute, is the winner of the 20th annual UHN Inventor of the Year Award for her work re-imagining the standards of care for patients living with sleep apnea through the development of the STOP-Bang clinical questionnaire.
A screening tool originally created to identify patients with undiagnosed sleep apnea for the prevention of critical incidents during surgery, STOP-Bang has broadened its adoption as a global standard diagnostic tool within 40 geographic regions and 500 institutions across a wide range of industries, informing preventative care and treatment for sleep apnea.
"It was curiosity and perseverance that led to the development of the STOP-Bang tool, and today, it is saving and improving lives around the globe," says Dr. Chung.
June 5, 2023
UHN, Canada's largest research hospital and medical innovation centre, has announced a drug discovery partnership with Providence Therapeutics, a leading Canadian biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics.
UHN and Providence will partner to develop novel mRNA-based vaccines and therapeutics for those living with difficult to treat cancers and infectious diseases.
The partnership, which was finalized with a signing ceremony on Friday, June 2 in MaRS Discovery District, will draw on UHN's renowned clinical research and discovery capabilities, as well as Providence's proprietary, clinically validated mRNA platform technology ..
.png)
September 25, 2023
Congratulations to University Health Network incubated company Adela on its next financing round! Proceeds from this second financing will be used to advance health options for cancer patients.
July 14, 2023
Nanogenix™ aims to develop emerging photo-immune cancer treatments. The company’s core technology is based on is based on Dr. Gang Zheng’s decade of research on naturally occurring lipid-based nanoparticles.
April 24, 2023
UHN tech ensures precise delivery of radiation during treatment and is now used world-wide
April 19, 2023
Adela's presentation at the American Association of Cancer Research (AACR) in April of 2023 focused on the ability of its genome-wide methylome enrichment platform, first discovered at UHN, to detect a broad set ...
September 22, 2021
“Congratulations to Lucid and FSD Pharma on taking this important step to accelerate potential treatment options for patients with multiple sclerosis based on technology developed at UHN. Working with our industry par...
%20(2).png)
November 18, 2021
Proceeds will fund the continued clinical development of CFI-400945, CFI-402257 and CFI-402411, the preclinical development of the Biologics and Cell Therapy platform. Financing led by Sino Biopharmaceutical and 3W Fu...
